EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diagnostic Accuracy of the Abbott BinaxNOW COVID‐19 Antigen Card Test, Puerto Rico

Zachary J Madewell iD, Chelsea G Major, Nathan Graff, Cameron Adams, Dania M Rodriguez, Tatiana Morales, Nicole A Medina Lopes, Rafael Tosado, Liliana Sánchez-González, Janice Perez-Padilla, Hannah R Volkman iD, Jorge Bertrán-Pasarell und 9 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Zachary J Madewell und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico. Hauptthemen laut MEDLINE: COVID-19, Sensitivity and Specificity, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCEZID CDC HHS, ACL HHS, National Center for Emerging and Zoonotic Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID‐19 pandemic underscored the need for rapid and accurate diagnostic tools. In August 2020, the Abbott BinaxNOW COVID‐19 Antigen Card test became available as a timely and affordable alternative for SARS‐CoV‐2 molecular testing, but its performance may vary due to factors including timing and symptomatology. This study evaluates BinaxNOW diagnostic performance in diverse epidemiological contexts.

Methods

Using RT‐PCR as reference, we assessed performance of the BinaxNOW COVID‐19 test for SARS‐CoV‐2 detection in anterior nasal swabs from participants of two studies in Puerto Rico from December 2020 to May 2023. Test performance was assessed by days post symptom onset, collection strategy, vaccination status, symptomatology, repeated testing, and RT‐PCR cycle threshold (Ct) values.

Results

BinaxNOW demonstrated an overall sensitivity of 84.1% and specificity of 98.8%. Sensitivity peaked within 1–6 days after symptom onset (93.2%) and was higher for symptomatic (86.3%) than asymptomatic (67.3%) participants. Sensitivity declined over the course of infection, dropping from 96.3% in the initial test to 48.4% in testing performed 7–14 days later. BinaxNOW showed 99.5% sensitivity in participants with low Ct values (≤ 25) but lower sensitivity (18.2%) for participants with higher Cts (36–40).

Conclusions

BinaxNOW demonstrated high sensitivity and specificity, particularly in early‐stage infections and symptomatic participants. In situations where test sensitivity is crucial for clinical decision‐making, nucleic acid amplification tests are preferred. These findings highlight the importance of considering clinical and epidemiological context when interpreting test results and emphasize the need for ongoing research to adapt testing strategies to emerging SARS‐CoV‐2 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Sensitivity and SpecificitySARS-CoV-2HumansPuerto RicoMaleAdultFemaleMiddle AgedAntigens, ViralYoung AdultAdolescentCOVID-19 Serological TestingAgedCOVID-19 Testing

Stichwörter der Autor:innen

OmicronPuerto RicoSARS‐CoV‐2diagnostic accuracyrapid antigen testsensitivity

Substanzen

Antigens, Viral

Autor:innen und Institutionen

  • Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
  • Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.
  • Auxilio Mutuo Hospital, San Juan, Puerto Rico.
  • Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.

ORCID-Profile: Zachary J Madewell, Hannah R Volkman, Melissa A Rolfes, Gabriela Paz-Bailey

Förderung

  • NCEZID CDC HHS
  • ACL HHS
  • National Center for Emerging and Zoonotic Infectious Diseases
  • Center for State, Tribal, Local and Territorial Support

Zitieren

APA

Madewell, Z. J., Major, C. G., Graff, N., Adams, C., Rodriguez, D. M., Morales, T., Medina Lopes, N. A., Tosado, R., Sánchez-González, L., Perez-Padilla, J., Volkman, H. R., Bertrán-Pasarell, J., Sainz de la Peña, D., Munoz-Jordan, J., Santiago, G. A., Lorenzi, O., Rivera-Amill, V., Rolfes, M. A., Paz-Bailey, G., …, & Wong, J. M. (2024). Diagnostic Accuracy of the Abbott BinaxNOW COVID‐19 Antigen Card Test, Puerto Rico. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13305

Vancouver

Madewell ZJ, Major CG, Graff N, Adams C, Rodriguez DM, Morales T, et al. Diagnostic Accuracy of the Abbott BinaxNOW COVID‐19 Antigen Card Test, Puerto Rico. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13305

BibTeX
@article{Madewell2024,
  author = {Madewell, Zachary J and Major, Chelsea G and Graff, Nathan and Adams, Cameron and Rodriguez, Dania M and Morales, Tatiana and Medina Lopes, Nicole A and Tosado, Rafael and Sánchez-González, Liliana and Perez-Padilla, Janice and Volkman, Hannah R and Bertrán-Pasarell, Jorge and Sainz de la Peña, Diego and Munoz-Jordan, Jorge and Santiago, Gilberto A and Lorenzi, Olga and Rivera-Amill, Vanessa and Rolfes, Melissa A and Paz-Bailey, Gabriela and Adams, Laura E and Wong, Joshua M},
  title = {Diagnostic Accuracy of the Abbott BinaxNOW COVID‐19 Antigen Card Test, Puerto Rico},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13305}
}
Kostenlos starten →